tirzepatide approved for osa Weight-loss drug Zepbound resolves sleep apnea in up to 52% of patients, Lilly says Obstructive sleep apnea with obesity:

It is often triggered by stress, illness, or medication changes

Tirzepatide weight loss data The SURMOUNT-1 trial enrolled 2,539 adults with obesity or overweight (BMI 27 or higher with at least one weight-related comorbidity) without type 2 diabetes

Intramuscular injection may cause localized pain and bruising because muscle tissue has different blood-flow rates than subcutaneous fat, potentially altering absorption speed

In the future, this therapy may be an effective option for adults who are struggling with obesity or excess weight, especially if previous attempts with diet and exercise alone have not led to lasting results

To solve this, we utilize advanced liposomal delivery